Mostrar el registro sencillo del ítem
dc.contributor.author
Berg, Gabriela Alicia
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Miksztowicz, Verónica Julieta
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.date.available
2018-03-19T20:36:34Z
dc.date.issued
2015-10
dc.identifier.citation
Berg, Gabriela Alicia; Miksztowicz, Verónica Julieta; Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes; Dove Press; Metalloproteinases in Medicine; 2; 10-2015; 51-59
dc.identifier.issn
2324-2027
dc.identifier.uri
http://hdl.handle.net/11336/39272
dc.description.abstract
Abstract: Matrix metalloproteinases (MMPs) constitute a family of more than 25 calcium-dependent, zinc-containing endopeptidases, synthesized by multiple cell types. These enzymes play an important role during physiological tissue development and remodeling and angiogenesis, as well as in pathophysiological conditions such as obesity and atherosclerotic process. Moreover, circulating levels of MMPs have emerged as potential biomarkers of cardiovascular disease. MMPs are regulated by different factors such as insulin resistance and obesity. Different components of the metabolic syndrome have been identified as possible stimulus for the synthesis and activity of MMPs. On the other hand, pro-inflammatory and anti-inflammatory cytokines, such as leptin and adiponectin, respectively, are associated with the regulation of MMPs. Leptin induces expression of MMP-2 activators as well as expression of MMP-2, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 in different human cells. Adiponectin may play a protective role in plaque rupture through selectively increasing TIMP expression. The hepatic manifestation of metabolic syndrome is nonalcoholic fatty liver disease (NAFLD). MMPs may remodel the liver parenchyma during the process of liver fibrosis. MMP-2 and MT1-MMP have been considered to be fibrogenic enzymes.There are few studies analyzing the role of MMPs in NAFLD, and most of them include study on mRNA expression, but even the results on their expression pattern remains controversial. MMPs could be considered as possible therapeutic targets. Different studies demonstrated that metformin, thiazolidinediones, and antibiotics could have inhibitory effects on the expression of MMPs; however, a rational study of lifestyle modifications as well as further studies of pharmacological therapies that influence MMPs are necessary to generate the information that physicians will probably need to improve the treatment of patients. The aim of this revision is to update the data about MMPs in the pathogenesis and progression of metabolic syndrome and the possible effect of different drugs on the behavior of these enzymes.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Dove Press
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc/2.5/ar/
dc.subject
Metalloproteinases
dc.subject
Metabolic Syndrome
dc.subject
Insulin Resistance
dc.subject
Non Alcoholic Fatty Liver
dc.subject
Metformin
dc.subject
Thiazolidinediones
dc.subject.classification
Salud Ocupacional
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Ciencias de la Salud
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Metalloproteinases in the pathogenesis and progression of metabolic syndrome: potential targets for improved outcomes
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-03-19T17:26:11Z
dc.journal.volume
2
dc.journal.pagination
51-59
dc.journal.pais
Nueva Zelanda
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Auckland
dc.description.fil
Fil: Berg, Gabriela Alicia. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
dc.description.fil
Fil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
dc.journal.title
Metalloproteinases in Medicine
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.2147/MNM.S88993
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.dovepress.com/metalloproteinases-in-the-pathogenesis-and-progression-of-metabolic-sy-peer-reviewed-article-MNM?utm_source=TrendMD&utm_medium=cpc&utm_campaign=Metalloproteinases_In_Medicine_TrendMD_0
Archivos asociados